Intrinsiqs

Is Xeris Biopharma Holdings, Inc. overvalued?

Xeris Biopharma Holdings, Inc. (XERS) — key valuation metrics and fundamentals.

No verdict
Price
$16.66
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$3.04B
Dividend yield
0.0%
Return on equity
-39.5%
Sector
Healthcare

See the full interactive analysis →

Fair value compares XERS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.